Key result
An autogenous inactivated vaccine against encephalomyocarditis in pigs proved to be safe and effective both in the laboratory and under field conditions.
Why the study?
Encephalomyocarditis poses a significant risk to pigs in Europe where no commercial vaccines are available.
Does an autogenous inactivated vaccine improve safety and effectiveness against encephalomyocarditis in pigs?
Does an autogenous inactivated vaccine improve safety and effectiveness against encephalomyocarditis in pigs?
An autogenous inactivated vaccine against encephalomyocarditis was developed and shown to be safe and effective in pigs in Italy.
Answers are grounded in this paper and cite their sources.
May support autogenous EMCV vaccine development in swine; leaves open translation to veterinary practice.
Encephalomyocarditis (EMC) is a rodent-borne disease that affects a variety of animal species, including humans, with pigs being particularly susceptible. It has been circulating for several years and has become endemic in certain areas of the world. While a commercial vaccine is available in the United States, no such vaccines are on offer in Europe, where EMC poses a significant risk. In this study, an autogenous vaccine for pigs was developed in response to a high mortality outbreak that occurred in an endemic area for EMCV in Italy. An inactivated vaccine formulated with an aluminium hydroxide adjuvant was administered in two doses to ensure optimal immunogenicity. The vaccine proved to be safe and effective both in the laboratory and under field conditions.
No takes yet. Share an insight, caveat, or question.
Tenuzzo et al. (2025) studied Encephalomyocarditis (EMC). Autogenous inactivated vaccine against encephalomyocarditis was evaluated on Safety and efficacy. An autogenous inactivated vaccine against encephalomyocarditis in pigs proved to be safe and effective both in the laboratory and under field conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: